Mabion S.A. (WSE: MAB)
Health Care · Biotechnology · PL
zł7.84
0.00% today · -17.2% 1Y
Mabion S.A. (WSE: MAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $34.31M and employs 202 people.
Over the last twelve months the share price has lost 17.2%, trading between 6.70 and 10.00.
Tweenvest scores Mabion S.A. across four factors: quality 47/100, value 60/100. Its strongest factor is value.
MAB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $34.31M
- Revenue (TTM)
- $4.73M
- P/E
- —
- EPS
- -3.53
- Dividend yield
- —
- Beta (5Y)
- 0.37
- 52-week high
- zł10.00
- 52-week low
- zł6.70
- Avg volume (3M)
- —
- Shares outstanding
- 16.16M
- Employees
- 202
- Next earnings
- —
About Mabion S.A.
Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing and commercialization of therapies designed to combat a wide range of diseases, including neoplastic (cancer), autoimmune, metabolic, and neurological disorders. Key products in its portfolio include MabionCD20 and MabionHER2. Established in 2007, Mabion S.A. maintains its headquarters in Konstantynów Lódzki, Poland.
- ISIN
- PLMBION00016
- Founded
- 2007
- Listed since
- Aug 10, 2010
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.